GlaxoSmithKline

Do more, feel better, live longer
Advanced search

Investors

Corporate press releases

[an error occurred while processing this directive] [an error occurred while processing this directive]

06 November 2009
World Health Organization Grants Prequalification for Global Use to GSK’s 10-Valent Synflorix™ Vaccine

Latest documents

 

29 September 2009
Raymond James Vaccines Conference

Dr Thomas Breuer, Senior Vice President Global Clinical R&D Vaccines & Chief Medical Officer, GSK Biologicals, gave a presentation to a group of around 40 investors on 28 September in Paris. Thomas provided an overview of GSK's vaccines business and late-stage pipeline.


Q3 results 2009


Product pipeline

Share price

LSE
1254p
+13.00

21 Nov 2009 closed
NYSE
41.53
0.00

21 Nov 2009 closed
London Stock Exchange price updated every minute Provided by

GSK RSS press release feed Subscribe to press release RSS feed


CEO Andrew Witty talks about latest progress of GSK’s strategic priorities:
GSK's strategic priorities
*

 

Share price analysis




Product pipeline

Building the best product pipeline in the industry

We aim to create the best product pipeline in the industry for the benefit of patients, consumers and society.

Our R&D organisation measures productivity by the number and innovation of the products it creates, and also by the commercial value of the products.

Find out more about our pipeline
Image of calendar

Financial calendar

Latest events in our financial calendar.